10月31日，安科生物涨5.09%，截至发稿，报10.74元/股，成交3.34亿元，换手率2.60%，总市值179.63 亿元。 创新药（159992）基金经理为马君、王帅。 截至发稿，马君累计任职时间13年61天，现任基金资产总规模427.38亿元，任职期间最佳基金回报 144.61%， 任职期间最差基金回报-75.62%。 王帅累计任职时间6年128天，现任基金资产总规模289.44亿元，任职期间最佳基金回报87.44%， 任职 期间最差基金回报-31.79%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，安徽安科生物工程(集团)股份有限公司位于安徽省合肥市长江西路669号高新区海关路K-1， 成立日期2000年9月28日，上市日期2009年10月30日，公司主营业务涉及细胞工程、基因工程、基因检 测、精准医疗等生物技术产品的研究开发、生产、销售。主营业务收入构成为：基因工程药88.24%， 外用贴膏11.67%，其他(补充)0.09 ...

Group 1 - The core viewpoint of the news is that Shenzhen Xinlitai Pharmaceutical Co., Ltd. has seen a stock price increase of 5.11%, reaching 57.21 CNY per share, with a total market capitalization of 63.779 billion CNY [1] - The company was established on November 3, 1998, and went public on September 10, 2009. Its main business involves the research, production, and sales of pharmaceuticals and medical devices [1] - The revenue composition of the company is as follows: formulations account for 81.69%, medical devices 8.54%, raw materials 7.17%, and others 2.59% [1] Group 2 - From the perspective of fund holdings, one fund under Yinhua Fund has a significant position in Xinlitai, holding 5.2574 million shares, which constitutes 2.63% of the fund's net value, ranking it as the eighth largest holding [2] - The fund, named Innovation Medicine (159992), has a total scale of 9.473 billion CNY and has achieved a year-to-date return of 37.91%, ranking 416 out of 4222 in its category [2] - The fund has a one-year return of 56.73%, ranking 1242 out of 3795, but has experienced a loss of 3.98% since its inception [2] Group 3 - The fund managers of Innovation Medicine are Ma Jun and Wang Shuai, with Ma having a tenure of 13 years and 5 days, managing assets totaling 33.304 billion CNY, and achieving a best return of 144.61% during his tenure [3] - Wang Shuai has a tenure of 6 years and 72 days, managing assets of 20.936 billion CNY, with a best return of 76.27% during his tenure [3]

Company Overview - Kangtai Biological Products Co., Ltd. is located in Nanshan District, Shenzhen, Guangdong Province, and was established on September 8, 1992. The company went public on February 7, 2017. Its main business involves the research, production, and sales of human vaccines [1]. - The revenue composition of Kangtai Biological is as follows: non-immunization program vaccines account for 93.70%, immunization program vaccines 3.71%, and others 2.59% [1]. Stock Performance - As of August 28, Kangtai Biological's stock price was 18.89 CNY per share, with a trading volume of 497 million CNY and a turnover rate of 2.96%. The total market capitalization is 21.099 billion CNY [1]. - The stock has experienced a decline for three consecutive days, with a cumulative drop of 5.55% during this period [1]. Shareholder Insights - Among the top ten circulating shareholders of Kangtai Biological, a fund under Yinhua Fund has reduced its holdings by 2.1063 million shares in the second quarter, now holding 6.2899 million shares, which represents 0.7% of the circulating shares. The estimated floating loss today is approximately 125,800 CNY, with a total floating loss of 6.9818 million CNY during the three-day decline [2]. - The fund, named Innovation Medicine (159992), was established on March 20, 2020, and has a current scale of 9.473 billion CNY. Year-to-date returns are 33.3%, ranking 738 out of 4222 in its category, while the one-year return is 53.07%, ranking 1544 out of 3776. Since its inception, it has incurred a loss of 7.19% [2]. Fund Management - The fund manager for Innovation Medicine is Ma Jun, who has a tenure of 12 years and 362 days, managing assets totaling 33.316 billion CNY. The best fund return during his tenure is 144.61%, while the worst is -75.58% [3]. - Another fund manager, Wang Shuai, has a tenure of 6 years and 64 days, managing assets of 20.936 billion CNY. His best fund return is 76.27%, and the worst is -32.36% [3].